Back to Search
Start Over
ESMO Consensus Conference on malignant lymphoma: management of ‘ultra-high-risk’ patients
- Source :
- Annals of Oncology, 29(8), 1687-1700. Oxford University Press
- Publication Year :
- 2018
- Publisher :
- Elsevier BV, 2018.
-
Abstract
- The European Society for Medical Oncology (ESMO) consensus conference onmalignant lymphoma was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (1) the elderly patient, (2) prognostic factors suitable for clinical use and (3) the 'ultra-high-risk' group. Before the conference, the expert panel was divided into three working groups; each group focused on one of these areas in order to address clinically relevant questions relating to that topic. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, each working group developed recommendations to address each of the questions devised by their group. These recommendations were then presented to the entire multidisciplinary panel and a consensus was reached. This manuscript presents recommendations regarding the management of the following 'ultra-high-risk' situations: (1) early central nervous system relapse of diffuse large B-cell lymphoma, (2) primary refractory Hodgkin lymphoma and (3) plasmablastic lymphoma. Results, including a summary of evidence supporting each recommendation, are detailed in this manuscript. All expert panel members approved this final article.
- Subjects :
- Consensus Development Conferences as Topic
Scientific literature
Medical Oncology
HIGH-DOSE CHEMOTHERAPY
0302 clinical medicine
Risk Factors
high-risk
Antineoplastic Combined Chemotherapy Protocols
B-cell lymphoma
Brentuximab vedotin
Societies, Medical
relapse
Clinical Trials as Topic
REFRACTORY HODGKIN LYMPHOMA
Hematology
Prognosis
Europe
Treatment Outcome
Oncology
030220 oncology & carcinogenesis
Practice Guidelines as Topic
CLINICAL-PRACTICE GUIDELINES
PHASE-II TRIAL
medicine.drug
PLASMABLASTIC LYMPHOMA
medicine.medical_specialty
MEDLINE
lymphoma
03 medical and health sciences
BRENTUXIMAB VEDOTIN
aggressive
Biomarkers, Tumor
medicine
Refractory Hodgkin Lymphoma
Humans
primary resistance
business.industry
CENTRAL-NERVOUS-SYSTEM
B-CELL LYMPHOMA
medicine.disease
Drug Resistance, Neoplasm
consensus
RITUXIMAB ERA
Family medicine
PRIMARY CNS LYMPHOMA
Radiotherapy, Adjuvant
Neoplasm Recurrence, Local
Working group
business
Diffuse large B-cell lymphoma
Plasmablastic lymphoma
030215 immunology
Subjects
Details
- ISSN :
- 09237534
- Volume :
- 29
- Database :
- OpenAIRE
- Journal :
- Annals of Oncology
- Accession number :
- edsair.doi.dedup.....a82b83190b9f7e3574ee0b30e7feb25c